In recent years, many biomarkers and biomarker types have been proposed and introduced for PCa detection; however, the best performance has always resulted from their combination, as in the case of PHID, outperforming PHI and PSAD in the detection of clinically significant PCa (AUC 0.851 vs. 0.819 and 0.813, respectively) [112] or the Stockholm-3 test consisting of a combination of blood biomarkers (fPSA, tPSA, intact PSA, microseminoprotein-β, MIC1, KLK2, genetic polymorphisms (232 SNPs in total) and clinical details such as age, previous biopsies and prostate exams [113]. This evidence concerns the gene KLK3 and posterior cortical atrophy.